Respirable nanocarriers as a promising strategy for antitubercular drug delivery

Journal of Controlled Release

Volumn 187, Issue , 2014, Pages 183-197

  Mehanna, Mohammed M ^a   Mohyeldin, Salma M ^a   Elgindy, Nazik A ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Inhalation therapy; Liposomes; Nanoparticles; Rifampicin; Tuberculosis

Indexed keywords

DISEASE CONTROL; DRUG INTERACTIONS; LIPOSOMES; NANOPARTICLES; NANOTECHNOLOGY; RESPIRATORY THERAPY; TOXICITY;

DRUG DELIVERY SYSTEM; INHALATION THERAPY; POLYMERIC NANOPARTICLES; RIFAMPICIN; SOLID LIPID NANOPARTICLE (SLN); SYSTEMIC TOXICITIES; TARGETING DRUG DELIVERIES; TUBERCULOSIS;

DRUG DELIVERY;

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DRUG CARRIER; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS RIFAMPICIN; KANAMYCIN A; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NANOCARRIER; POLYGLACTIN; POLYMER; PYRAZINAMIDE; RIFAMPICIN; SOLID LIPID NANOPARTICLE; STREPTOMYCIN; TUBERCULOSTATIC AGENT; NANOPARTICLE;

DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG PARENCHYMA; MICELLE; NANOTECHNOLOGY; NONHUMAN; PATIENT COMPLIANCE; PRIMARY INFECTION; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; ANIMAL; METABOLISM;

ADMINISTRATION, INHALATION; ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; RESPIRATORY SYSTEM;

EID: 84902772220     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.05.038     Document Type: Review

References (129)

1. S.K. Sahoo, and V. Labhasetwar Nanotech approaches to drug delivery and imaging Drug Discov. Today 8 2003 1112 1120 10.1016/S1359-6446(03)02903-9
2. S.K. Sahoo, S. Parveen, and J.J. Panda The present and future of nanotechnology in human health care Nanomedicine 3 2007 20 31 10.1016/j.nano.2006.11.008
3. M.L. Forrest, and G.S. Kwon Clinical developments in drug delivery nanotechnology Adv. Drug Deliv. Rev. 60 2008 861 862 10.1016/j.addr.2008.02.013
4. L. Mei, Z. Zhang, L. Zhao, L. Huang, X.-L. Yang, J. Tang, and S.-S. Feng Pharmaceutical nanotechnology for oral delivery of anticancer drugs Adv. Drug Deliv. Rev. 65 2013 880 890 10.1016/j.addr.2012.11.005
5. A. Sosnik, Á.M. Carcaboso, R.J. Glisoni, M.A. Moretton, and D.A. Chiappetta New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery Adv. Drug Deliv. Rev. 62 2010 547 559 10.1016/j.addr.2009.11.023
6. Global tuberculosis control: surveillance, planning, financing: WHO report 2012 http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502-eng. pdf 2012
7. N. Padayatchi, and G. Friedland Decentralised management of drug-resistant tuberculosis (MDR- and XDR-TB) in South Africa: an alternative model of care Int. J. Tuberc. Lung Dis. 12 2008 978 980
8. P. Muttil, C. Wang, and A.J. Hickey Inhaled drug delivery for tuberculosis therapy Pharm. Res. 26 2009 2401 2416 10.1007/s11095-009-9957-4
9. D. Dube, G.P. Agrawal, and S.P. Vyas Tuberculosis: from molecular pathogenesis to effective drug carrier design Drug Discov. Today 17 2012 760 773 10.1016/j.drudis.2012.03.012
10. R. Shegokar, L. Al Shaal, and K. Mitri Present status of nanoparticle research for treatment of tuberculosis J. Pharm. Pharm. Sci. 14 2011 100 116
11. J.A. Caminero, G. Sotgiu, A. Zumla, and G.B. Migliori Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis Lancet Infect. Dis. 10 2010 621 629 10.1016/s1473-3099(10)70139-0
12. R. Pandey, and Z. Ahmad Nanomedicine and experimental tuberculosis: facts, flaws, and future Nanomedicine 7 2011 259 272 10.1016/j.nano.2011.01.009
13. P.M. Small, and P.I. Fujiwara Management of tuberculosis in the United States N. Engl. J. Med. 345 2001 189 200 10.1056/nejm200107193450307
14. E.S. Guy, and A. Mallampalli Managing TB in the 21st century: existing and novel drug therapies Ther. Adv. Respir. Dis. 2 2008 401 408 10.1177/1753465808099522
15. Treatment of tuberculosis guidelines WHO Report 4th ed. 2010 (http://whqlibdoc.who.int/publications/2010/9789241547833-eng.pdf)
16. M.A. Arbex, C. Varella Mde, H.R. Siqueira, and F.A. Mello Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs J. Bras. Pneumol. 36 2010 626 640
17. D. Yee, C. Valiquette, M. Pelletier, I. Parisien, I. Rocher, and D. Menzies Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis Am. J. Respir. Crit. Care Med. 167 2003 1472 1477 10.1164/rccm.200206-626OC
18. L. du Toit, V. Pillay, and M. Danckwerts Tuberculosis chemotherapy: current drug delivery approaches Respir. Res. 7 2006 1 18 10.1186/1465-9921-7- 118
19. R. Zaleskis The side-effects of TB therapy Breathe 2 2005 69 73
20. V.A. Desai, and S.B. Agarwal Isoniazid toxicity J. Indian Acad. Clin. Med. 5 2004 83 85
21. B. Saifullah, M.Z. Hussein, and S.H. Hussein Al Ali Controlled-release approaches towards the chemotherapy of tuberculosis Int. J. Nanomedicine 7 2012 5451 5463
22. A. Misra, A.J. Hickey, C. Rossi, G. Borchard, H. Terada, K. Makino, P.B. Fourie, and P. Colombo Inhaled drug therapy for treatment of tuberculosis Tuberculosis 91 2011 71 81 10.1016/j.tube.2010.08.009
23. J.C. Sung, B.L. Pulliam, and D.A. Edwards Nanoparticles for drug delivery to the lungs Trends Biotechnol. 25 2007 563 570 10.1016/j.tibtech.2007.09.005
24. K. Nahar, N. Gupta, R. Gauvin, S. Absar, B. Patel, V. Gupta, A. Khademhosseini, and F. Ahsan In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals Eur. J. Pharm. Sci. 49 2013 805 818 10.1016/j.ejps.2013.06.004
25. Y.-Y. Huang, and C.-H. Wang Pulmonary delivery of insulin by liposomal carriers J. Control. Release 113 2006 9 14 10.1016/j.jconrel.2006.03.014
26. J. Zhang, L. Wu, H.-K. Chan, and W. Watanabe Formation, characterization, and fate of inhaled drug nanoparticles Adv. Drug Deliv. Rev. 63 2011 441 455 10.1016/j.addr.2010.11.002
27. J.S. Patton, C.S. Fishburn, and J.G. Weers The lungs as a portal of entry for systemic drug delivery Proc. Am. Thorac. Soc. 1 2004 338 344 10.1513/pats.200409-049TA
28. J. Yu, and Y.W. Chien Pulmonary drug delivery: physiologic and mechanistic aspects Crit. Rev. Ther. Drug Carrier Syst. 14 1997 395 453
29. F. Andrade, D. Rafael, M. Videira, D. Ferreira, A. Sosnik, and B. Sarmento Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases Adv. Drug Deliv. Rev. 65 2013 1816 1827 10.1016/j.addr.2013. 07.020
30. G.A. Ferron, S. Upadhyay, R. Zimmermann, and E. Karg Model of the deposition of aerosol particles in the respiratory tract of the rat. II. Hygroscopic particle deposition J. Aerosol Med. Pulm. Drug Deliv. 26 2013 101 119
31. G.A. Ferron Aerosol properties and lung deposition Eur. Respir. J. 7 1994 1392 1394
32. R. Pandey, and G.K. Khuller Antitubercular inhaled therapy: opportunities, progress and challenges J. Antimicrob. Chemother. 55 2005 430 435 10.1093/jac/dki027
33. M. Smola, T. Vandamme, and A. Sokolowski Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases Int. J. Nanomedicine 3 2008 1 19
34. H.M. Mansour, Y.S. Rhee, and X. Wu Nanomedicine in pulmonary delivery Int. J. Nanomedicine 4 2009 299 319
35. S. Al-Qadi, A. Grenha, D. Carrión-Recio, B. Seijo, and C. Remuñán-López Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations J. Control. Release 157 2012 383 390 10.1016/j.jconrel.2011.08.008
36. C. Rundfeldt, H. Steckel, H. Scherliess, E. Wyska, and P. Wlaź Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis Eur. J. Pharm. Biopharm. 83 2013 44 53 10.1016/j.ejpb.2012.09.018
37. M. Beck-Broichsitter, C. Schweiger, T. Schmehl, T. Gessler, W. Seeger, and T. Kissel Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery J. Control. Release 158 2012 329 335 10.1016/j.jconrel.2011.10.030
38. X. Li, F.G. Vogt, D. Hayes Jr., and H.M. Mansour Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery Eur. J. Pharm. Sci. 52 2014 191 205 10.1016/j.ejps.2013.10.016
39. R.R. Patlolla, M. Chougule, A.R. Patel, T. Jackson, P.N. Tata, and M. Singh Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers J. Control. Release 144 2010 233 241 10.1016/j.jconrel.2010.02.006
40. Y.Z. Li, X. Sun, T. Gong, J. Liu, J. Zuo, and Z.R. Zhang Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles Pharm. Res. 27 2010 1977 1986 10.1007/s11095-010-0201-z
41. C. Jaafar-Maalej, V. Andrieu, A. Elaissari, and H. Fessi Beclomethasone-loaded lipidic nanocarriers for pulmonary drug delivery: preparation, characterization and in vitro drug release J. Nanosci. Nanotechnol. 11 2011 1841 1851
42. K. Dharmala, J.W. Yoo, and C.H. Lee Development of chitosan-SLN microparticles for chemotherapy: in vitro approach through efflux-transporter modulation J. Control. Release 131 2008 190 197 10.1016/j.jconrel.2008.07.034
43. N. El-Gendy, E.M. Gorman, E.J. Munson, and C. Berkland Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution J. Pharm. Sci. 98 2009 2731 2746 10.1002/jps.21630
44. A. Trapani, S. Di Gioia, N. Ditaranto, N. Cioffi, F.M. Goycoolea, A. Carbone, M. Garcia-Fuentes, M. Conese, and M.J. Alonso Systemic heparin delivery by the pulmonary route using chitosan and glycol chitosan nanoparticles Int. J. Pharm. 447 2013 115 123 10.1016/j.ijpharm.2013.02.035
45. A. Makhlof, M. Werle, Y. Tozuka, and H. Takeuchi Nanoparticles of glycol chitosan and its thiolated derivative significantly improved the pulmonary delivery of calcitonin Int. J. Pharm. 397 2010 92 95 10.1016/j.ijpharm.2010.07. 001
46. J. Kreuter Drug delivery to the central nervous system by polymeric nanoparticles: What do we know? Adv. Drug Deliv. Rev. 20 2014 10.1016/j.addr.2013.08.008http://dx.doi.org/10.1016/j.addr.2013.08.008
47. T. Lebhardt, S. Roesler, M. Beck-Broichsitter, and T. Kissel Polymeric nanocarriers for drug delivery to the lung Drug Deliv. Sci. Technol. 20 2010 171 180
48. M. Yang, H. Yamamoto, H. Kurashima, H. Takeuchi, T. Yokoyama, H. Tsujimoto, and Y. Kawashima Design and evaluation of poly(dl-lactic-co-glycolic acid) nanocomposite particles containing salmon calcitonin for inhalation Eur. J. Pharm. Sci. 46 2012 374 380 10.1016/j.ejps.2012.02.024
49. M. Yang, H. Yamamoto, H. Kurashima, H. Takeuchi, T. Yokoyama, H. Tsujimoto, and Y. Kawashima Design and evaluation of inhalable chitosan-modified poly (dl-lactic-co-glycolic acid) nanocomposite particles Eur. J. Pharm. Sci. 47 2012 235 243 10.1016/j.ejps.2012.05.016
50. D. Yoo, K. Guk, H. Kim, G. Khang, D. Wu, and D. Lee Antioxidant polymeric nanoparticles as novel therapeutics for airway inflammatory diseases Int. J. Pharm. 450 2013 87 94 10.1016/j.ijpharm.2013.04.028
51. E. Rytting, J. Nguyen, X. Wang, and T. Kissel Biodegradable polymeric nanocarriers for pulmonary drug delivery Expert Opin. Drug Deliv. 5 2008 629 639 10.1517/17425247.5.6.629
52. J.P. Rao, and K.E. Geckeler Polymer nanoparticles: preparation techniques and size-control parameters Prog. Polym. Sci. 36 2011 887 913 10.1016/j.progpolymsci.2011.01.001
53. A. Kumari, S.K. Yadav, and S.C. Yadav Biodegradable polymeric nanoparticles based drug delivery systems Colloids Surf. B 75 2010 1 18 10.1016/j.colsurfb.2009.09.001
54. T. Lebhardt, S. Roesler, H.P. Uusitalo, and T. Kissel Surfactant-free redispersible nanoparticles in fast-dissolving composite microcarriers for dry-powder inhalation Eur. J. Pharm. Biopharm. 78 2011 90 96 10.1016/j.ejpb.2010.12.002
55. K. Kho, and K. Hadinoto Optimizing aerosolization efficiency of dry-powder aggregates of thermally-sensitive polymeric nanoparticles produced by spray-freeze-drying Powder Technol. 214 2011 169 176 10.1016/j.powtec.2011.08. 010
56. F. Andrade, M. Videira, D. Ferreira, and B. Sarmento Nanocarriers for pulmonary administration of peptides and therapeutic proteins Nanomedicine 6 2011 123 141 10.2217/nnm.10.143
57. S. Malathi, and S. Balasubramanian PLGA nanoparticles for anti tuberculosis drug delivery Adv. Mater. Res. 584 2012 465 469
58. J.M. Anderson, and M.S. Shive Biodegradation and biocompatibility of PLA and PLGA microspheres Adv. Drug Deliv. Rev. 28 1997 5 24 10.1016/S0169-409X(97) 00048-3
59. C. Hu, H. Feng, and C. Zhu Preparation and characterization of rifampicin-PLGA microspheres/sodium alginate in situ gel combination delivery system Colloids Surf. B 95 2012 162 169 10.1016/j.colsurfb.2012.02.030
60. R. Pandey, A. Sharma, A. Zahoor, S. Sharma, G.K. Khuller, and B. Prasad Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis J. Antimicrob. Chemother. 52 2003 981 986 10.1093/jac/dkg477
61. D.A. Groneberg, C. Peiser, Q.T. Dinh, J. Matthias, P.R. Eynott, W. Heppt, I. Carlstedt, C. Witt, A. Fischer, and K.F. Chung Distribution of respiratory mucin proteins in human nasal mucosa Laryngoscope 113 2003 520 524 10.1097/00005537-200303000-00023
62. A. Sharma, S. Sharma, and G.K. Khuller Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis J. Antimicrob. Chemother. 54 2004 761 766
63. J.C. Sung, D.J. Padilla, L. Garcia-Contreras, J.L. Verberkmoes, D. Durbin, C.A. Peloquin, K.J. Elbert, A.J. Hickey, and D.A. Edwards Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery Pharm. Res. 26 2009 1847 1855 10.1007/s11095-009-9894-2
64. K. Ohashi, T. Kabasawa, T. Ozeki, and H. Okada One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis J. Control. Release 135 2009 19 24 10.1016/j.jconrel.2008.11.027
65. K. Tomoda, T. Ohkoshi, T. Nakajima, and K. Makino Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles Colloids Surf. B 64 2008 70 76 10.1016/j.colsurfb.2008.01.016
66. K. Tomoda, T. Ohkoshi, Y. Kawai, M. Nishiwaki, T. Nakajima, and K. Makino Preparation and properties of inhalable nanocomposite particles: effects of the temperature at a spray-dryer inlet upon the properties of particles Colloids Surf. B 61 2008 138 144 10.1016/j.colsurfb.2007.07.016
67. P.H. Moghaddam, V. Ramezani, E. Esfandi, A. Vatanara, M. Nabi-Meibodi, M. Darabi, K. Gilani, and A.R. Najafabadi Development of a nano-micro carrier system for sustained pulmonary delivery of clarithromycin Powder Technol. 239 2013 478 483 10.1016/j.powtec.2013.02.025
68. S. Hirano, H. Seino, Y. Akiyama, and I. Nonaka Biocompatibility of chitosan by oral and intravenous administrations Polym. Mater. Sci. Eng. 59 1988 897 901
69. H.H. Tonnesen, and J. Karlsen Alginate in drug delivery systems Drug Dev. Ind. Pharm. 28 2002 621 630 10.1081/ddc-120003853
70. C.-M. Lehr, J.A. Bouwstra, E.H. Schacht, and H.E. Junginger In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers Int. J. Pharm. 78 1992 43 48 10.1016/0378-5173(92)90353-4
71. A. Grenha, B. Seijo, and C. Remuñán-López Microencapsulated chitosan nanoparticles for lung protein delivery Eur. J. Pharm. Sci. 25 2005 427 437 10.1016/j.ejps.2005.04.009
72. P.S. Pourshahab, K. Gilani, E. Moazeni, H. Eslahi, M.R. Fazeli, and H. Jamalifar Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid J. Microencapsul. 28 2011 605 613 10.3109/02652048.2011.599437
73. Z. Ahmad, S. Sharma, and G.K. Khuller Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis Int. J. Antimicrob. Agents 26 2005 298 303 10.1016/j.ijantimicag.2005.07.012
74. R.H. Müller, K. Mäder, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177 10.1016/S0939-6411(00)00087-4
75. W. Mehnert, and K. Mäder Solid lipid nanoparticles: production, characterization and applications Adv. Drug Deliv. Rev. 64 2012 83 101 10.1016/j.addr.2012.09.021
76. A. Zur Mühlen, C. Schwarz, and W. Mehnert Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism Eur. J. Pharm. Biopharm. 45 1998 149 155 10.1016/S0939-6411(97)00150-1
77. S. Weber, A. Zimmer, and J. Pardeike Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art Eur. J. Pharm. Biopharm. 86 1 2014 7 22 10.1016/j.ejpb.2013.08. 013
78. A.A. Date, M.D. Joshi, and V.B. Patravale Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles Adv. Drug Deliv. Rev. 59 2007 505 521 10.1016/j.addr.2007.04.009
79. C. Schwarz, W. Mehnert, J.S. Lucks, and R.H. Müller Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization J. Control. Release 30 1994 83 96 10.1016/0168-3659(94)90047-7
80. K. Westesen Novel lipid-based colloidal dispersions as potential drug administration systems - expectations and reality Colloid Polym. Sci. 278 2000 608 618 10.1007/s003969900257
81. R. Pandey, and G.K. Khuller Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis Tuberculosis 85 2005 227 234 10.1016/j.tube.2004.11.003
82. B.E. Gilbert Liposomal aerosols in the management of pulmonary infections J. Aerosol Med. 9 1996 111 122
83. Z. Drulis-Kawa, and A. Dorotkiewicz-Jach Liposomes as delivery systems for antibiotics Int. J. Pharm. 387 2010 187 198 10.1016/j.ijpharm.2009.11.033
84. M.M. Mehanna, H.A. Elmaradny, and M.W. Samaha Ciprofloxacin liposomes as vesicular reservoirs for ocular delivery: formulation, optimization, and in vitro characterization Drug Dev. Ind. Pharm. 35 2009 583 593 10.1080/03639040802468024
85. A. Samad, Y. Sultana, and M. Aqil Liposomal drug delivery systems: an update review Curr. Drug Deliv. 4 2007 297 305
86. A. Sharma, and U.S. Sharma Liposomes in drug delivery: progress and limitations Int. J. Pharm. 154 1997 123 140 10.1016/S0378-5173(97)00135-X
87. L. Willis, D. Hayes Jr., and H.M. Mansour Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery Lung 190 2012 251 262 10.1007/s00408-011-9360-x
88. M. Beck-Broichsitter, M. Rieger, R. Reul, T. Gessler, W. Seeger, and T. Schmehl Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations Eur. J. Pharm. Biopharm. 84 2013 106 114 10.1016/j.ejpb.2012.12.003
89. K.M. Taylor, and J.M. Newton Liposomes for controlled delivery of drugs to the lung Thorax 47 1992 257 259
90. O.R. Justo, and A.M. Moraes Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation Drug Deliv. 10 2003 201 207 10.1080/713840401
91. M. Zaru, C. Sinico, A. De Logu, C. Caddeo, F. Lai, M.L. Manca, and A.M. Fadda Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation J. Liposome Res. 19 2009 68 76 10.1080/08982100802610835
92. R. Pandey, S. Sharma, and G.K. Khuller Nebulization of liposome encapsulated antitubercular drugs in guinea pigs Int. J. Antimicrob. Agents 24 2004 93 94 10.1016/j.ijantimicag.2004.04.004
93. G. Chimote, and R. Banerjee Lung surfactant dysfunction in tuberculosis: effect of mycobacterial tubercular lipids on dipalmitoylphosphatidylcholine surface activity Colloids Surf. B 45 2005 215 223 10.1016/j.colsurfb.2005.08.014
94. G. Chimote, and R. Banerjee In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis J. Biomed. Mater. Res. B Appl. Biomater. 94 2010 1 10 10.1002/jbm.b.31608
95. M. Chougule, B. Padhi, and A. Misra Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics Int. J. Nanomedicine 2 2007
96. M. Chougule, B. Padhi, and A. Misra Development of spray dried liposomal dry powder inhaler of Dapsone AAPS Pharm. Sci. Tech. 9 2008 47 53 10.1208/s12249-007-9024-6
97. N. Changsan, H.K. Chan, F. Separovic, and T. Srichana Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation J. Pharm. Sci. 98 2009 628 639 10.1002/jps.21441
98. W. Rojanarat, N. Changsan, E. Tawithong, S. Pinsuwan, H.K. Chan, and T. Srichana Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies Int. J. Mol. Sci. 12 2011 4414 4434 10.3390/ijms12074414
99. W. Rojanarat, T. Nakpheng, E. Thawithong, N. Yanyium, and T. Srichana Levofloxacin proliposomes: opportunities for use in lung tuberculosis Pharmaceutics 4 2012 385 412
100. W. Rojanarat, T. Nakpheng, E. Thawithong, N. Yanyium, and T. Srichana Inhaled pyrazinamide proliposome for targeting alveolar macrophages Drug Deliv. 19 2012 334 345 10.3109/10717544.2012.721144
101. A. Patil-Gadhe, and V. Pokharkar Single step spray drying method to develop proliposomes for inhalation: A systematic study based on quality by design approach Pulm. Pharmacol. Ther. 27 2 2014 197 207 10.1016/j.pupt.2013.07. 006
102. M.V. Vadakkan, K. Annapoorna, K.C. Sivakumar, S. Mundayoor, and G.S. Kumar Dry powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage Int. J. Nanomedicine 8 2013 2871 2885 10.2147/ijn.s47456
103. J.M. Abdulla, Y.T. Tan, and Y. Darwis Rehydrated lyophilized rifampicin-loaded mPEG-DSPE formulations for nebulization AAPS Pharm. Sci. Tech. 11 2010 663 671
104. H.M. Cabral Marques, J. Hadgraft, I.W. Kellaway, and G. Taylor Studies of cyclodextrin inclusion complexes. III. The pulmonary absorption of β-, DM-β- and HP-β-cyclodextrins in rabbits Int. J. Pharm. 77 1991 297 302 10.1016/0378-5173(91)90330-Q
105. L. Matilainen, T. Toropainen, H. Vihola, J. Hirvonen, T. Jarvinen, P. Jarho, and K. Jarvinen In vitro toxicity and permeation of cyclodextrins in Calu-3 cells J. Control. Release 126 2008 10 16 10.1016/j.jconrel.2007.11.003
106. M.E. Brewster, and T. Loftsson Cyclodextrins as pharmaceutical solubilizers Adv. Drug Deliv. Rev. 59 2007 645 666 10.1016/j.addr.2007.05.012
107. V. Stella, and R. Rajewski Cyclodextrins: their future in drug formulation and delivery Pharm. Res. 14 1997 556 567 10.1023/A:1012136608249
108. T. Kinnarinen, P. Jarho, K. Järvinen, and T. Järvinen Pulmonary deposition of a budesonide/γ-cyclodextrin complex in vitro J. Control. Release 90 2003 197 205 10.1016/S0168-3659(03)00176-7
109. L. Matilainen, K. Järvinen, T. Toropainen, E. Näsi, S. Auriola, T. Järvinen, and P. Jarho In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A Int. J. Pharm. 318 2006 41 48 10.1016/j.ijpharm.2006.03.009
110. M. Stojanov, H.M. Nielsen, and K.L. Larsen Cyclodextrins: efficient biocompatible solubilizing excipients for bromhexine liquid and semi-solid drug delivery systems Int. J. Pharm. 422 2012 349 355 10.1016/j.ijpharm.2011.10.023
111. W. Yang, K.T. Chow, B. Lang, N.P. Wiederhold, K.P. Johnston, and R.O. Williams Iii In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution Eur. J. Pharm. Sci. 39 2010 336 347 10.1016/j.ejps.2010.01.001
112. T. Loftsson, and M.E. Brewster Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization J. Pharm. Sci. 85 1996 1017 1025
113. B. Evrard, P. Bertholet, M. Gueders, M.P. Flament, G. Piel, L. Delattre, A. Gayot, P. Leterme, J.M. Foidart, and D. Cataldo Cyclodextrins as a potential carrier in drug nebulization J. Control. Release 96 2004 403 410 10.1016/j.jconrel.2004.02.010
114. S. Sawatdee, H. Phetmung, and T. Srichana Sildenafil citrate monohydrate-cyclodextrin nanosuspension complexes for use in metered-dose inhalers Int. J. Pharm. 455 2013 248 258 10.1016/j.ijpharm.2013.07.023
115. F. Tewes, J. Brillault, W. Couet, and J.-C. Olivier Formulation of rifampicin-cyclodextrin complexes for lung nebulization J. Control. Release 129 2008 93 99 10.1016/j.jconrel.2008.04.007
116. A. Schoubben, P. Blasi, M.L. Marenzoni, L. Barberini, S. Giovagnoli, C. Cirotto, and M. Ricci Capreomycin supergenerics for pulmonary tuberculosis treatment: preparation, in vitro, and in vivo characterization Eur. J. Pharm. Biopharm. 83 2013 388 395 10.1016/j.ejpb.2012.11.005
117. M.R. Gwinn, and V. Vallyathan Nanoparticles: health effects - pros and cons Environ. Health Perspect. 114 2006 1818 1825
118. S. Gill, R. Löbenberg, T. Ku, S. Azarmi, W. Roa, and E.J. Prenner Nanoparticles: characteristics, mechanisms of action, and toxicity in pulmonary drug delivery - a review J. Biomed. Nanotechnol. 3 2007 107 119 10.1166/jbn.2007.015
119. M. Beck-Broichsitter, O.M. Merkel, and T. Kissel Controlled pulmonary drug and gene delivery using polymeric nano-carriers J. Control. Release 161 2012 214 224 10.1016/j.jconrel.2011.12.004
120. W.H. De Jong, and P.J. Borm Drug delivery and nanoparticles: applications and hazards Int. J. Nanomedicine 3 2008 133 149
121. G. Oberdorster Lung particle overload: implications for occupational exposures to particles Regul. Toxicol. Pharmacol. 21 1995 123 135 10.1006/rtph.1995.1017
122. P.G. Rogueda, and D. Traini The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects Expert Opin. Drug Deliv. 4 2007 595 606
123. L.A. Dailey, N. Jekel, L. Fink, T. Gessler, T. Schmehl, M. Wittmar, T. Kissel, and W. Seeger Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung Toxicol. Appl. Pharmacol. 215 2006 100 108 10.1016/j.taap.2006.01.016
124. N. Scholer, H. Hahn, R.H. Muller, and O. Liesenfeld Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages Int. J. Pharm. 231 2002 167 176 10.1016/S0378- 5173(01)00882-1
125. N. Scholer, C. Olbrich, K. Tabatt, R.H. Muller, H. Hahn, and O. Liesenfeld Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages Int. J. Pharm. 221 2001 57 67 10.1016/S0378-5173(01)00660-3
126. C. Olbrich, N. Scholer, K. Tabatt, O. Kayser, and R.H. Muller Cytotoxicity studies of Dynasan 114 solid lipid nanoparticles (SLN) on RAW 264.7 macrophages - impact of phagocytosis on viability and cytokine production J. Pharm. Pharmacol. 56 2004 883 891
127. W.G. Kreyling, M. Semmler, F. Erbe, P. Mayer, S. Takenaka, H. Schulz, G. Oberdorster, and A. Ziesenis Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low J. Toxicol. Environ. Health A 65 2002 1513 1530 10.1080/ 00984100290071649
128. G. Oberdorster, Z. Sharp, V. Atudorei, A. Elder, R. Gelein, W. Kreyling, and C. Cox Translocation of inhaled ultrafine particles to the brain Inhal. Toxicol. 16 2004 437 445 10.1080/08958370490439597
129. M.M. Bailey, and C.J. Berkland Nanoparticle formulations in pulmonary drug delivery Med. Res. Rev. 29 2009 196 212 10.1002/med.20140